ATE418550T1 - 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen - Google Patents

8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen

Info

Publication number
ATE418550T1
ATE418550T1 AT04764687T AT04764687T ATE418550T1 AT E418550 T1 ATE418550 T1 AT E418550T1 AT 04764687 T AT04764687 T AT 04764687T AT 04764687 T AT04764687 T AT 04764687T AT E418550 T1 ATE418550 T1 AT E418550T1
Authority
AT
Austria
Prior art keywords
treatment
piperazinyl
quinoline derivatives
cns diseases
cns
Prior art date
Application number
AT04764687T
Other languages
English (en)
Inventor
Christopher Norbert Johnson
Stephen Frederick Moss
Malcolm M Tait
David Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE418550T1 publication Critical patent/ATE418550T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04764687T 2003-08-29 2004-08-26 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen ATE418550T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320320.5A GB0320320D0 (en) 2003-08-29 2003-08-29 Novel compounds

Publications (1)

Publication Number Publication Date
ATE418550T1 true ATE418550T1 (de) 2009-01-15

Family

ID=28686602

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764687T ATE418550T1 (de) 2003-08-29 2004-08-26 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen

Country Status (7)

Country Link
US (1) US20080275040A1 (de)
EP (1) EP1660483B1 (de)
JP (1) JP2007504114A (de)
AT (1) ATE418550T1 (de)
DE (1) DE602004018658D1 (de)
GB (1) GB0320320D0 (de)
WO (1) WO2005021530A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
EP1558582B1 (de) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
WO2007108744A2 (en) * 2006-03-17 2007-09-27 Astrazeneca Ab Novel quinazolines as 5-ht6 modulators
WO2007108743A2 (en) * 2006-03-17 2007-09-27 Astrazeneca Ab Novel quinazolines as 5-ht6 modulators ii
EP1999121A1 (de) * 2006-03-17 2008-12-10 AstraZeneca AB Neue tetraline als 5-ht6-modulatoren
US20090203708A1 (en) * 2006-07-05 2009-08-13 Korea Research Institute Of Chemical Technology Novel substituted-1-h-quinazoline-2,4-dione derivatives, preparation method thereof and pharmaceutical composition containing the same
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
EP3166924B1 (de) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatische heterocyclische derivate und pharmazeutische anwendungen davon
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
PH12021551324A1 (en) 2019-01-08 2022-04-25 Kyorin Seiyaku Kk 15-pgdh inhibitor
US12304897B2 (en) 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
KR100889718B1 (ko) * 2001-06-11 2009-03-23 바이오비트럼 에이비(피유비엘) 치환 술폰아미드 화합물, cns 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법
JP2005511625A (ja) * 2001-11-14 2005-04-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 向精神薬としてのピラゾール誘導体
SI1497266T1 (sl) * 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
WO2003080608A2 (en) * 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline and aza-indole derivatives and their use as 5-ht6 ligands

Also Published As

Publication number Publication date
WO2005021530A1 (en) 2005-03-10
GB0320320D0 (en) 2003-10-01
EP1660483A1 (de) 2006-05-31
JP2007504114A (ja) 2007-03-01
EP1660483B1 (de) 2008-12-24
DE602004018658D1 (de) 2009-02-05
US20080275040A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
CY1113306T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
DE602004018658D1 (de) 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns-erkrankungen
DE60309852D1 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
HRP20041005B1 (hr) Kinolinski i izokinolinski derivati, postupci njihove proizvodnje, te naäśini njihove primjene kao sredstava za spreäśavanje (suzbijanje) upalnih procesa
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
ATE402165T1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
EA200701252A1 (ru) Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
TW200503710A (en) Novel compounds
DE602004007672D1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
ATE433966T1 (de) Methylendipiperidinderivate
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
TW200514781A (en) Novel compounds
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
UY26426A1 (es) Nuevos compuestos
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
BRPI0409958A (pt) quinolinas de benzofuranil- e benzotienil-piperazinil quinolinas e métodos para o seu uso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties